STOCK TITAN

Haemonetics Corporation (HAE) 10-K Filings

HAE NYSE

Here are the 10-K annual reports from Haemonetics Corporation (HAE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow HAE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HAE filings page.

Rhea-AI Summary

Haemonetics Corporation provides an overview of its global medical technology business in Plasma, Blood Center and Hospital segments, highlighting products that support plasma collection, blood management and hospital procedures.

The filing notes that Plasma and Hospital are viewed as the main long-term growth drivers, while Blood Center faces more challenging markets. In fiscal 2026, Plasma and Blood Center represented 39.3% and 16.6% of total revenue, and Hospital 44.1%. One Plasma customer generated 13% of total net revenues, and the ten largest customers accounted for 44%, underscoring customer concentration risk.

The company reports an aggregate market value of non‑affiliate equity of $2.23 billion as of September 27, 2025 and 45.4 million common shares outstanding as of May 15, 2026. Key themes include continued investment in R&D, new FDA clearances for NexSys PCS and VASCADE MVP XL, complex global regulatory obligations, supply chain and cybersecurity risks, and competition from large medtech peers across all business lines.